samedan logo
 
 
 
spacer
home > ebr > autumn 2001 > prion safety of biopharmaceuticals and blood-related products
PUBLICATIONS
European Biopharmaceutical Review

Prion Safety of Biopharmaceuticals and Blood-Related Products

Biopharmaceutical products such as recombinant proteins, monoclonal antibodies, vaccines, and blood- and plasma-related products, must fulfil complex requirements regarding quality and safety. Many of these products have often had contact with bovine material, either as a constituent of the product itself, or by indirect contact during production. Since bovine spongiform encephalopathy (BSE) was identified in the UK in 1986, the use of bovine material in medicinal products has prompted action by national and international regulatory authorities to assure the continued safety of these products.This article provides a brief overview of the subject of prion safety, the actions of international regulatory authorities, and the consequences for the manufacturing industry of medicinal products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Melanie Dippel, Corporate Communications Manager
at NewLab BioQuality AG in Germany Melanie Dippel is currently Corporate Communications Manager at NewLab BioQuality AG - a Germany-based company providing GLP-compliant quality control testing and analysis on all major types of biopharmaceuticals.
With more than four years' experience in public relations work for different biotech organisations, she joined NewLab BioQuality AG in February of this year. Melanie received her Diploma in Molecular Biology and Biochemistry from the University of Düsseldorf in Germany.

spacer
Melanie Dippel
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Altasciences Acquires Sinclair Research and Continues to Expand Preclinical Platform

Laval, Quebec, January 4, 2022 – Altasciences, an integrated CRO/CDMO offering pharmaceutical and biotechnology companies a seamless solution to early-stage drug development from lead candidate selection to clinical proof of concept, announced today the completed acquisition of Sinclair Research, a preclinical CRO located in the Midwest. Complementing existing locations on the East and West Coast, the new site will facilitate even greater access to Altasciences’ preclinical services across the US.
More info >>

White Papers

A Rules Based Approach to Labelling and Artwork Management

Kallik

Many organisations today are experiencing unprecedented demands from regulatory authorities and consumers alike for product labelling to be made clearer and more informative. Forthcoming regulations (including the new EU MDR regulations coming into force May 2020) also require that labelling content to be published electronically in addition to print. As companies seek to continuously differentiate themselves in established markets as well as gain entry into new territories, the increase in both volume and complexity of product and market variations will have a direct impact on labelling.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement